Zeo ScientifiX (ZEOX) Change in Accured Expenses (2012 - 2026)
Zeo ScientifiX (ZEOX) posted quarterly Change in Accured Expenses of $236000.0 for Q2 2026, up 88.8% year-over-year from $125000.0 in Q2 2025, and up 2722.22% quarter-over-quarter from -$9000.0 in Q1 2026.
Zeo ScientifiX (ZEOX) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Zeo ScientifiX's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $236000.0 for Q2 2026.
- In Q2 2026, Change in Accured Expenses rose 88.8% year-over-year to $236000.0; the TTM figure through Apr 2026 stood at $262000.0 (up 645.83% YoY), while the FY2025 annual figure was $200000.0, up 123.5% from the prior year.
- Change in Accured Expenses for Q2 2026 stood at $236000.0, up from -$9000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $438000.0 in Q3 2025, with the low at -$403000.0 in Q4 2025.
- The 5-year median for Change in Accured Expenses is $48763.5 (2022), against an average of $46922.7.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 238.18% in 2024, then surged 627.71% in 2025.
- Zeo ScientifiX's Change in Accured Expenses stood at $333826.0 in 2022, then sank by 44.88% to $184000.0 in 2023, then sank by 170.65% to -$130000.0 in 2024, then tumbled by 210.0% to -$403000.0 in 2025, then surged by 158.56% to $236000.0 in 2026.
- Business Quant data shows ZEOX's Change in Accured Expenses at $236000.0 in Q2 2026, -$9000.0 in Q1 2026, and -$403000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Zeo ScientifiX | 10.51 Mn | 8.67 Mn | 2.06 Mn | 236,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 236,000.00 |
| Apr 30, 2026 | 236,000.00 |
| Jan 31, 2026 | -9,000.00 |
| Jan 31, 2026 | -9,000.00 |
| Oct 31, 2025 | -403,000.00 |
| Oct 31, 2025 | -403,000.00 |
| Jul 31, 2025 | 438,000.00 |
| Jul 31, 2025 | 438,000.00 |
| Apr 30, 2025 | 125,000.00 |
| Apr 30, 2025 | 125,000.00 |
| Jan 31, 2025 | 40,000.00 |
| Jan 31, 2025 | 40,000.00 |
| Oct 31, 2024 | -130,000.00 |
| Oct 31, 2024 | -130,000.00 |
| Jul 31, 2024 | -83,000.00 |
| Jul 31, 2024 | -83,000.00 |
| Apr 30, 2024 | -266,000.00 |
| Apr 30, 2024 | -266,000.00 |
| Jan 31, 2024 | -372,000.00 |
| Jan 31, 2024 | -372,000.00 |